Enabling personalized cancer care

We use state-of-the-art technologies to develop cancer-specific monitoring tests and provide physicians with optimal therapy-decision support. Based on a simple blood sample, we offer innovative and robust solutions to closely, precisely and reliably monitor cancer and treatment response. This ensures that patients receive the best possible medical care at optimal cost efficiency.

Learn more about Oncobit

Testimonial

Oncobit’s PM platform is transforming melanoma management. With its digital PCR-based approach, it delivers highly sensitive and quantitative detection of ctDNA markers, empowering clinicians to monitor disease progression and treatment response closely and reliably to improve clinical management.

Prof. Dr. med. Reinhard Dummer, Professor at University Zürich, Skin Cancer Expert, Senior Medical Advisor at Oncobit

Our Journey

February 2025

Oncobit Achieves ISO 13485 Recertification and Expands IVDR Certification to Cover Additional Indications

We are proud to announce our successful recertification of ISO 13485, and the expansion of our IVDR certification to cover additional indications.

Prof. Reinhard Dummer joins Oncobit as Senior Medical Advisor

We are excited to welcome Prof. Reinhard Dummer to Oncobit as Senior Medical Advisor. Prof. Dummer is a highly cited Professor of Dermatology at the University Zurich. He is renowned for his extensive contributions to skin cancer research, particularly in melanoma and non-melanoma skin cancers at the University Hospital Zurich. As Senior Medical Advisor, Prof. Dummer will play a key role in guiding Oncobit’s clinical strategies, and fostering collaborations with leading medical institutions and industry partners.

Oncobit closes 1.5M Pre-Series A Financing Round

We are thrilled to announce that we closed a 1.5M CHF Pre-Series A Financing round. A huge thank you to our existing and new investors for supporting our vision of enabling personalized cancer care. The investment will enable us to continue to grow and strengthen our position in the cancer monitoring market.